SCHEMBL7380726

SCHEMBL7380726

CC(C)(C)OC(=O)c1nc(CCCC(=O)O)ccc1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.38
NR1H2 P55055 3/20 0.38
NR1H3 Q13133 1/20 0.36
HSD17B10 Q99714 1/20 0.35
LTB4R Q15722 1/20 0.34
ALDH1A1 P00352 3/20 0.33
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HDAC3 O15379 1/20 0.33
MAPK1 P28482 1/20 0.33
ADRA1A P35348 1/20 0.33
HDAC4 P56524 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14634358 0.80 CNR1 (0.37) ALDH1A1MAPTSMN1; SMN2SLC7A5LMNA
SCHEMBL7375668 0.79 MEN1 (0.37) MAPK1KDM4EGAA
SCHEMBL28037738 0.73 ALDH1A1 (0.36) ALDH1A1MAPTSMN1; SMN2SLC7A5LMNA
SCHEMBL14634345 0.73 GRM5 (0.47) ALDH1A1MAPTSMN1; SMN2LMNAKDM4E
SCHEMBL27837947 0.72 LMNA (0.41) ALDH1A1MAPTLMNAKDM4EGLA
SCHEMBL30322440 0.72 LMNA (0.41) ALDH1A1MAPTLMNAKDM4EGLA
SCHEMBL1518152 0.69 SCN3A (0.39) RXRANR1H2NR1H3HSD17B10SMN1; SMN2
SCHEMBL7380720 0.68 GLS (0.41) LMNAITGAVITGB6KDM4EGAA
SCHEMBL27803032 0.68 HPGDS (0.38) ALDH1A1MAPTSLC7A5LMNAKDM4E
SCHEMBL3740210 0.67 ALDH1A1 (0.43) HSD17B10ALDH1A1MAPTSMN1; SMN2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6294549-B1 COMPOUNDS USEFUL FOR INHIBITING RESTENOSIS, ANGIOGENESIS, ATHEROSCLEROSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, INFLAMMATION OR TUMOR GROWTH. MERCK & CO., INC. 2001-09-25 US disclosed
US-5952306-A INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND INHIBITING THE AGGREGATION OF BLOOD PLATELETS; INHIBITING OSTEOCLAST CELLULAR ADHESION TO BONE SURFACES MERCK & CO., INC. (US) 1999-09-14 US disclosed
EP-0880511-A4 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-06-16 EP disclosed
EP-0880511-A1 INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-12-02 EP disclosed
WO-1997026250-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-07-24 WO disclosed